FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Grassley, Wyden Invite Drugmakers to Testify at Pricing Hearing

Feb. 12, 2019

Leaders of the Senate Finance Committee invited seven leading drug companies to testify in an upcoming hearing on drug pricing — and hinted that they will take a more aggressive approach if the drugmakers decline the invitation.

Committee Chair Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-Ore.) invited AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi to testify at the Feb. 26 hearing. The letters are invitations rather than subpoenas, but the senators referred to their previous remarks at a Jan. 29 hearing about compelling testimony.

“This is an opportunity for companies that produce life-saving treatments to explain how they price these treatments and whether the status quo is acceptable,” the senators said in a joint statement. “Patients and taxpayers deserve to hear from leaders in the industry about what’s behind this unsustainable trend and what can be done to lower costs.”

View today's stories